An interventional study of CAREN and Control group in Healthy Individuals (Controls), Parkinson Disease and Multiple Sclerosis, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo — 6 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · IRCCS Centro Neurolesi Bonino Pulejo.
Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 13 with no phase, and was the 8th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →6 of the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo are open now, in 1 country. Recruiting first, the newest first:
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 40–70
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–75
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 40–80
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 45–80
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–90 · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 150 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 60 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.
2 of the studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838975IRCCS Centro Neurolesi Bonino PulejoVirtual Reality Rehabilitation for Cognitive, Emotional, and Motor Recovery in Neurological Disorders | 2027-09-29 |
| NCT07434089IRCCS Centro Neurolesi Bonino PulejoImpact of C-Mill Rehabilitation on the Gut-Brain Axis in Parkinson's Disease | 2027-10-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate motor responses in healthy subjects and patients with movement disorders, brain and spinal cord injury, neuromuscular diseases, or cardiovascular diseases.
This study aims to evaluate the effectiveness of traditional physical activities combined with innovative interventions such as cryotherapy, ultrasound therapy, laser therapy, transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS). It will also assess the impact of proprioceptive stimuli provided by either the immersive virtual reality (CAREN), or visuo-cognitive-motor enhancement (S.V.T.A.), and music therapy.
The main questions it aims to answer are:
How do these interventions affect motor activities and their functional recovery? What are the temporal and spatial changes in activation sequences related to motor learning and maintenance? When there is a comparison group: Researchers will compare outcomes between different intervention arms (e.g., physical activity with advanced devices vs. traditional methods) to find out if the advanced interventions result in better motor control and functional recovery.
Participants will:
Objectives
Primary Objectives Investigating Motor Gesture Control: Study the sensory-motor structures and their connectivity in healthy participants and patients with neurological, cardiovascular, or neuromuscular conditions. This includes analyzing responses to advanced interventions such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and the CAREN (Computer Assisted Rehabilitation Environment) system.
Understanding Central Control Mechanisms: Assess spatial and temporal changes in brain activity during motor training and recovery processes, leveraging advanced neuroimaging techniques (e.g., fMRI, dtMRI, NIRS).
Secondary Objectives Postural Disorder Prevention: Develop strategies to enhance postural stability and prevent related disorders, improving sports performance and the quality of life in patients with neurodegenerative conditions.
Integration of Imaging and Psychometric Data: Employ multimodal data to uncover brain function patterns and inform rehabilitation strategies, contributing to personalized recovery protocols and optimized training methods.
Methodology Study Design
This is an interventional study aimed at evaluating the metabolic, functional, and neurophysiological aspects of motor responses in participants subjected to intensive physical and cognitive training. By combining traditional therapies with innovative technologies (e.g., CAREN, IVS3, AlterG, tDCS, TMS), the study will explore:
Central nervous system activation and connectivity. Temporal and spatial dynamics of motor learning and maintenance. The role of proprioceptive, visual, and auditory inputs in motor coordination.
Phases of Study Phase 1: Recruitment and Baseline Assessments Participants will be recruited through direct communication and provided with detailed study information.
Baseline evaluations will include:
Clinical and medical-sports assessment. Neuropsychological evaluation (e.g., MoCA, TMT, Stroop Test). Postural and gait analysis. Baseline imaging (MRI, EEG). Phase 2: Intervention and Data Collection
Participants will undergo structured interventions:
Physiotherapy sessions combined with neuromodulation techniques. Training on the CAREN system to assess and improve motor and postural functions.
Use of advanced devices for electromyographic data collection, oxygen consumption measurements, and 3D gait analysis.
Imaging and functional assessments will be repeated post-intervention.
Phase 3: Data Analysis and Dissemination Collected data will be anonymized, processed using advanced imaging and statistical algorithms, and analyzed for correlations between training responses and functional recovery.
Results will be published in high-impact international journals. Technologies and Assessments
Neuroimaging Techniques:
Functional and structural MRI (including T1-weighted, T2-weighted, and DTI sequences).
Analysis of mean diffusivity and fractional anisotropy to evaluate white matter integrity.
NIRS to assess cortical hemodynamics during tasks.
Neurophysiological Tools:
EEG and ECG to monitor the electrical activity of the brain and heart. Surface electromyography (EMG) to evaluate muscle activation patterns.
Advanced Rehabilitation Devices:
CAREN system: A virtual environment platform for motor and postural rehabilitation.
Alter-G/Gait Trainer 3 for assisted gait training. IVS3 FLIR system for thermal imaging of muscular activity.
Neuropsychological Assessments:
Comprehensive cognitive evaluation, including MoCA, TMT, Stroop, and PASAT. Auditory anamnesis and visuomotor training (e.g., S.V.T.A.).
Population The study aims to recruit 150 participants, including healthy individuals and patients aged 18-70 years with neurological conditions (stroke, dementia, Parkinson's Disease, Multiple Sclerosis, Spinal Cord Injury). Detailed inclusion and exclusion criteria ensure the selection of suitable candidates.
Ethical and Administrative Aspects All participants will provide informed consent per ethical guidelines (Declaration of Helsinki and GDPR compliance).
The relevant Ethics Committee approves the study, with no additional costs or compensations.
Results will be transparently reported, adhering to international research standards.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The subjects will undergo baseline examinations including MRI, spirometry, surface electromyography, 3D gait analysis, postural assessment and stabilometric analysis, O2 consumption measurement, neuropsychological assessment, ECG, and EEG. Subsequently, the healthy subjects (approximately 50) will undergo intensive aerobic and anaerobic training (including sensory-motor-cognitive training) and exercises on the CAREN platform. For the other 25 participants, transcranial magnetic stimulation (TMS)/transcranial direct current stimulation (tDCS) and music therapy will be added.
Other: Control group
As for the neurological patients (50), they will undergo posture and gait rehabilitation using the CAREN platform, while the other 25 will receive additional enhancement through non-invasive neuromodulation. This constitutes the other arm of the study.
Device: CAREN
The interventions include proprioceptive stimuli combined with specific rehabilitation protocols, such as Tabata training, plyometric training, and visual-cognitive-motor enhancement with the S.V.T.A. method. Healthy subjects and athletes (about 50) will participate in intensive aerobic and anaerobic training, including sensory-motor-cognitive training and exercises on the CAREN platform. Another 25 participants will have TMS/tDCS and music therapy added to their regimen. Regarding neurological patients, 50 participants will undergo posture and gait rehabilitation using the CAREN platform, while 25 will receive non-invasive neuromodulation to enhance their rehabilitation outcomes. This arm of the study focuses on the recovery of motor and cognitive functions. This study uses the CAREN system as a tool for physical rehabilitation in neurological and healthy participants. The device is not being investigated for new indications and the study is conducted entirely in Italy.
the control group is typically the group that does not receive the experimental treatment or intervention, serving as a baseline to compare the effects of the intervention. However, in the context you're describing with healthy subjects and athletes, here's how it's structured: Healthy subjects and athletes (around 50 participants) will undergo: Intensive aerobic and anaerobic training Sensory-motor-cognitive training Additionally, 25 of these participants will receive: Transcranial Magnetic Stimulation (TMS) Transcranial Direct Current Stimulation (tDCS) Music therapy This approach allows for a comparison between the effects of the physical and cognitive training alone versus the enhanced effects when combined with neuromodulation (TMS, tDCS) and music therapy. This design will help in assessing the added value of these interventions on performance
Amplitude of Motor-Related Event-Related Potentials (ERPs) During Gesture Execution Assessed by EEG.
Motor-related EEG activity will be recorded during the execution of standardized gestures. The primary outcome is the mean amplitude (in µV) of specific ERP components (e.g., N200, P300) over motor cortex electrodes. Data will be averaged across trials for each participant and reported as group means ± standard deviation. Differences between healthy participants and clinical groups will be assessed using appropriate statistical tests.
Time frame: Baseline (T0), post-intervention (T1, 12 weeks after baseline), and follow-up (T2, 3 months post-intervention).
Respiratory Exchange Ratio (RER) During Submaximal Exercis
Metabolic efficiency will be assessed through the respiratory exchange ratio (RER = VCO₂/VO₂) during submaximal steady-state exercise. RER will be measured at standardized workload levels and summarized as mean ± SD. Comparisons between groups or timepoints will assess changes in substrate utilization patterns.
Time frame: Baseline (T0), post-intervention (T1, 12 weeks after baseline), and follow-up (T2, 3 months post-intervention).
Change in Global Cognitive Function as Measured by MoCA Total Score
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The primary outcome is the change in total score (range: 0-30) from baseline to post-intervention. Data will be summarized as mean ± SD and analyzed using paired or independent statistical tests, depending on the study design.
Time frame: Baseline (T0), post-intervention (T1, 12 weeks after baseline), and follow-up (T2, 3 months post-intervention).
Plan to share: Yes — we plan to share individual participant data (IPD) with other researchers. The data will be made available through a secure platform, ensuring participant confidentiality and compliance with ethical guidelines. Access will be granted under a data use agreement that requires anonymization and outlines permitted uses. We encourage collaborative research and publication of findings derived from the shared data for a period of five years following the study's completion.
Supporting information: Statistical analysis plan, Clinical study report
Time frame: Individual participant data (IPD) and supporting information will be available starting at the commencement of the study and will remain accessible for five years.
Access criteria: Access to individual participant data (IPD) and supporting information will be granted to qualified researchers, including academic institutions, healthcare organizations, and other entities involved in neurorehabilitation research. Researchers will be able to access the anonymized IPD, study protocols, and relevant supporting information such as assessment measures and data collection methods. Access will be facilitated through a secure online data-sharing platform, where approved users can download the data after signing a data use agreement that outlines the terms of use and ensures compliance with ethical guidelines and participant confidentiality. This process aims to promote collaboration while safeguarding the integrity and privacy of the participants involved in the study.
Started May 2024 (actual). Primary completion is estimated for Dec 2028, 55 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 55 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion May 2026 → Dec 2028 and completion Dec 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Centro Neurolesi Bonino Pulejo